Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Women and lung cancer – the role of sex hormones


Researchers at the Austrian Academy of Sciences’ Institute for Molecular Biotechnology (IMBA) have identified a remarkable connection between sex hormones and primary lung cancer. A medicine that has already been approved for osteoporosis and bone metastasis could now be used to prevent a particularly aggressive form of adenocarcinoma.

Every 30 seconds someone in the world dies of lung cancer. Lung cancer metastases that can develop after a primary tumour are particularly unpredictable and aggressive. Just one in ten people survive for more than five years after being diagnosed with advanced lung cancer. In the 1950s it was proven that chemicals found in tobacco smoke can cause the cells in our body to mutate.

The upper panel shows normal lung tumors, and the lower one shows lung tumors after RANK pathway inhibition

(c) IMBA

This breakthrough identified one of the leading causes for a wide variety of cancers. It is primarily the cells in the lungs that are affected by smoking as they are directly exposed to these carcinogenic chemicals. Like all cancers, lung cancer is a very complex disease which is triggered by a combination of different environmental and genetic factors. An international team led by IMBA Scientific Director Josef Penninger has now identified a remarkable connection between sex hormones and lung cancer.

Gender medicine puzzle solved

RANK/RANKL are proteins that help determine the body’s bone remodelling and repair function. This bone metabolism mechanism is, in turn, steered by female sex hormones, and plays a role in the normal physiology of the female breast and breast cancer. Until recently, a number of, in many cases, controversial studies proposed that women are more susceptible to lung cancer than men and that lung cancer is more aggressive in women. Until recently, scientists had yet to identify a sex-based trigger for lung cancer.

According to the latest research findings, the RANK/RANKL system plays a significant part in the development of lung cancer, as reported in a new study published in Genes and Development by an international team led by Josef Penninger. The good news: a medicine approved for the treatment of osteoporosis and tested in clinical trials studying hormone-related and congenital breast cancer could prove to be an effective weapon in the fight against lung cancer.

Missing link: RANK/RANKL

One common type of lung cancer, adenocarcinoma, which is caused by a mutation of the KRAS gene, is characterised by its particularly aggressive progression. And it was precisely this carcinoma that researchers looked at in the lungs of mice and people. They found that the previously identified RANK/RANKL signal path is active in the cancer cells and promotes rapid tumour growth.

“For some time, researchers believed that there was a connection between female sex hormones and this aggressive type of lung cancer. And now we have pinpointed the ‘missing link’. In this carcinoma, RANK/RANKL works like a kind of amplifier, particularly in lung cancer stem cells which can be targeted and switched off,” explained Shuan Rao, primary author of the current publication and postdoctoral research fellow at IMBA.

Administering Denosumab, an antibody that has already received regulatory approval, significantly slowed the progression of the disease. With the aggressive KRAS variant of lung cancer, the connection between sex hormones and the development of cancer could open the door to new therapy options. “I am always fascinated by how mysterious and interconnected the body’s signal paths are.

To start with, we were able to find the mechanisms behind osteoporosis with the help of RANK/RANKL, then we succeeded in explaining hormone-related breast cancer and now we have landed at lung cancer,” said Josef Penninger, commenting on the huge potential of his discoveries. Based on earlier data, which showed that lung cancer patients participating in a Denosumab clinical trial lived significantly longer, the blockage of RANKL by the antibody will be tested in a phase 3 study of advanced lung cancer (SPLENDOUR trial: survival improvement in lung cancer induced by denosumab therapy).

“Nobody knew how it worked. Our data now show for the first time that RANK/RANKL has a direct impact on the development of lung cancer – presumably at a very early stage – and that there is a molecular link to gender and sex hormones. As a result, clinical studies should be conducted in much earlier phases of lung cancer development, with a particular focus on the development of cancer in women,” noted Penninger.

Original publication: Rao et al. „RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer", Genes & Development, doi/10.1101/gad.304162.117.

About IMBA
IMBA - Institute of Molecular Biotechnology is one of the leading biomedical research institutes in Europe focusing on cutting-edge functional genomics and stem cell technologies. IMBA is located at the Vienna Biocenter, the vibrant cluster of universities, research institutes and biotech companies in Austria. IMBA is a basic research institute of the Austrian Academy of Sciences, the leading national sponsor of non-university academic research.

About the Vienna BioCenter
The Vienna BioCenter (VBC) is a leading life sciences location in Europe, offering an extraordinary combination of research, education and business on a single campus. About 1,700 employees, more than 1,300 students, 88 research groups, 18 biotech companies, and scientists from more than 69 nations create a highly dynamic environment. This research was part of the VBC PhD Programme.

Weitere Informationen:

Mag. Ines Méhu-Blantar | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht Nonstop Tranport of Cargo in Nanomachines
20.11.2018 | Max-Planck-Institut für molekulare Zellbiologie und Genetik

nachricht Researchers find social cultures in chimpanzees
20.11.2018 | Universität Leipzig

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nonstop Tranport of Cargo in Nanomachines

Max Planck researchers revel the nano-structure of molecular trains and the reason for smooth transport in cellular antennas.

Moving around, sensing the extracellular environment, and signaling to other cells are important for a cell to function properly. Responsible for those tasks...

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Optical Coherence Tomography: German-Japanese Research Alliance hosted Medical Imaging Conference

19.11.2018 | Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

Latest News

Nonstop Tranport of Cargo in Nanomachines

20.11.2018 | Life Sciences

Researchers find social cultures in chimpanzees

20.11.2018 | Life Sciences

When AI and optoelectronics meet: Researchers take control of light properties

20.11.2018 | Physics and Astronomy

Science & Research
Overview of more VideoLinks >>>